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Open access undBackground and purpose: For stereotactic body radiotherapy (SBRT), typically a scheme of 60 Gy in 3–8
fractions is applied, producing local tumour control rates around 90%. The dose speciﬁcation is in one
point only and ignores possible underdosages at the edge of the planning target volume (PTV). We inves-
tigated the doses at the edge of the PTV and correlated this with local tumour control with the aim to
shed light on the radiation dose needed to eradicate stage I NSCLC.
Materials and methods: Published data on the freedom from local progression (FFLP) data from SBRT and
accelerated high-dose conventional radiotherapy series for stage I NSCLC with a follow up of at least
30 months were included. The EQD2,T was calculated from the dose at the periphery of the PTV.
Results: Fifteen studies for SBRT (1076 patients) showed a median FFLP of 88.0 ± 10.4% with a median
EQD2,T of 76.9 ± 17.4 Gy. The median FFLP was 87.6 ± 6.0% for the accelerated schedules with an EQD2,T
of 86.9 ± 39.1 Gy, respectively. No signiﬁcant relation was found between FFLP and the EQD2,T (p = 0.23).
Conclusions: Several fractionated and accelerated schedules with equal biological doses achieve the same
tumour control rates as SBRT. Lower, but more uniform doses to the whole PTV may be sufﬁcient to
achieve similar control rates, with the possibility to deliver SBRT in adapted schedules, beneﬁcial to cen-
trally located tumours in the vicinity of critical structures like the oesophagus and great vessels.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 105 (2012) 145–149The incidence of cancer is increasing in Europe, with an esti-
mated number of 3.2 million new cases a year. Lung cancer ranks
third in terms of incidence, but is the main cause of cancer-related
death. About 25% of lung cancer patients present with early stage
disease [1]. For patients with clinical stages I and II disease with
no medical contraindications, surgery is the ﬁrst treatment of
choice showing 5-year survival rates of about 60–80% for stage I
and 40–50% for stage II, respectively [1]. However for patients
who are medically or technically unﬁt for surgery and for patients
refusing surgery, stereotactic body radiotherapy (SBRT), also called
stereotactic ablative radiotherapy (SABR), is an alternative with lo-
cal control rates >90% at 3 years [2–7]. Most guidelines recom-
mend doses of 48–60 Gy in 3–8 fractions delivered in about
3 weeks [8]. However, these hypo-fractionation schedules might
be too toxic with regard to late side effects if critical structures,
such as main bronchi or large vessels are within the planning tar-
get volume (PTV). In a single institution phase II study by Timmer-
man and colleagues including 70 patients with early stage,
inoperable NSCLC tumours located anywhere within the lung,diation Oncology (MAASTRO
mental Biology, Maastricht
ds.
A. van Baardwijk).
Open access under CC BY-NC-ND lice
er CC BY-NC-ND license.including centrally located tumours [9]. In the analysis of high-
grade toxicity (grade 3–5), tumour location (hilar or pericentral
versus peripheral) was a strong predictor for grade 3–5 toxicity
(p = 0.004). Patients treated for tumours in the peripheral lung
had 2-year freedom from severe toxicity estimated at 83% as com-
pared with 54% in patients with central tumours. Therefore, cen-
trally located tumours often ‘conventional’ radiotherapy
fractionation, commonly consisting of 60–66 Gy given in 2 Gy per
day, 5 days a week is chosen. However, reported local control rates
are poor and highly variable, varying between 6% and 70%
[7,10,11], although there seems to be a trend for better local con-
trol with higher biologically-effective doses [12,13]. This should
not be surprising in view of the data of Martel et al., showing that
the D50 (which is the dose needed to achieve 50% tumour control)
at 30 months would be 84.5 Gy, delivered in once-daily 2 Gy per
fraction [14]. A similar biologically effective dose may be delivered
using accelerated schedules with multiple daily fractions or with
hypo-fractionation [15–19]. Another strategy for centrally located
early stage tumours is the use of more ‘‘risk-adaptive strategies’’
for SBRT [20–22]. Haasbeek and colleagues reported on a SBRT
scheme, in which the number of fractions and total dose used is
dependent on the T-stage, the localisation of the tumour and there-
fore the risk of normal tissue toxicity [23]. In 9 out of 63 patients
with centrally located tumours treated with 60 Gy in 8 fractions,nse.
146 SBRT for stage I NSCLCit could not be excluded that their death had a cardiopulmonary
cause. Early results with Cyber Knife technology in patients with
central tumours showed no severe toxicities [24].
Published SBRT studies vary considerably with regard to clinical
target volume (CTV) and planning target volume (PTV) margins,
methods of dose prescription, fractionation schemes, planning
parameters, dose calculation algorithms used, planning tech-
niques, use of 4D CT scans, quality assurance during treatment;
all of which might inﬂuence the outcome [25]. As an example,
the dose at the edge of the PTV ranges widely between studies as
well as the degree of dose inhomogeneity within the target volume
to achieve a steep dose falloff. Furthermore, with regard to calcula-
tion algorithms some series have been reported using type A dose
calculation algorithms, i.e. models that are primarily based on elec-
tronic path length (EPL) scaling for in-homogeneity corrections,
whereas others have used type B models that in an approximate
way consider changes in lateral electron transport. The more ad-
vanced type B models should be used for dose calculations for lung
tumour treatments [26]. As a consequence, the reported doses are
not comparable between series. We hypothesise that the absorbed
dose in the PTV will be signiﬁcantly less than the reported dose at
the dose speciﬁcation point for most studies. As a consequence, the
dose required to eradicate stage I tumours, especially small T1 tu-
mours, may be overestimated based on the doses reported. Avoid-
ing this ‘‘overkill’’ may be beneﬁcial and may result in an even
better therapeutic ratio that would allow one to treat central le-
sions with hypo-fractionation.
Here, accelerated high-dose conventional radiotherapy with
larger margins was compared with several SBRT schemes, to inves-
tigate which hypo-fractionated schedule would have the best ther-
apeutic ratio, and hence be applicable for central lesions without
loss of efﬁcacy.Methods and materials
In this systematic review, a literature search from January 1,
1995 to December 31st, 2011 was performed using PubMed to se-
lect studies for SBRT/SABR and/or accelerated radiotherapy for
stage I NSCLC (cT1-2N0M0 according to the UICC 7th Edition).
Studies were included if they: (1) provided 3 year freedom from lo-
cal progression (FFLP) data, (2) had a median follow-up of at least
30 months, (3) were published in English, (4) accepted or pub-
lished as full text paper or meeting abstract, and (5) doses to the
edge of the tumour should be described or could be estimated
according to the allowed dose inhomogeneity.
Additional information was obtained through personal corre-
spondence with the authors. The biologically equivalent dose in
2 Gy fractions (EQD2) was calculated from the dose at the edge of
the PTV using the linear quadratic formula with a/b of 10 Gy for tu-
mour/early responding tissue and a/b of 3 Gy was assumed for late
effects. The EQD2 was adjusted for overall treatment time (EQD2,T)
to take into account accelerated repopulation after 21 days [27],
but knowing that these estimations may be less appropriate with
fraction sizes over 10 Gy [28].
EQD2;T ¼ D 
dþ a=b
2þ a=bMAXð0; T  TrefÞ  Dprolif
where the second term is zero for T 6 Tref and equal to Dprolif
(Dprolif = 0.6) multiplied by the number of days beyond Tref for
T > Tref. To compare SBRT with accelerated high-dose conformal
radiotherapy, patients from the CALGB 39904 study and the MAAS-
TRO NCT00573040 trial were included [12,13]. From the latter only
patients with stage I disease were included in this analysis and the
overall survival for this group was updated. To compare thedifferent schedules the therapeutic ratio was calculated by dividing
the EQD2,T for tumour by the EQD2 for late effects.Statistics
Considering that a small sample size of a subset of patients will
increase the uncertainty of the estimated treatment effect, the data
were weighted by the number of patients included in a subset of
patients. Results (FFLP, EQD2 for tumour and late effects, therapeu-
tic ratio) are expressed as median ± standard deviation (SD) and
range. A linear regression analysis was performed to analyse the
dose–effect relation. The data were analysed in SPSS version 17.0
(SPSS Inc., Chicago, IL).Results
Of the 54 studies considered, 15 studies (1076 patients) met our
inclusion criteria of having a follow-up of at least 30 months, and
reporting data on both 3-year freedom from local progression
and dose prescription [7,29–42] (Table 1).
The prescribed total doses ranged from 30 to 72.5 Gy in 3–11
fractions. All patients had stage I disease (66% T1 and 34% T2
tumours).
Results were separated for different schedules if more than one
schedule was used within a study and were weighted by the num-
ber of patients included in a subset of a study. The two accelerated,
fractionated trials [12,13] delivered a mean dose of 70 Gy in 24
fractions (CALGB) and 75.6 Gy in 42 fractions (MAASTRO). Re-
ported incidences of severe side effects were similar in all series,
being less than 10%.
The median FFLP for all SBRT schedules was 88.0 ± 10.4% (range
49–100%), with a median EQD2,T for tumour of 76.9 ± 17.4 Gy (50–
126 Gy) and for late effects of 119.2 ± 35.4 Gy (72.6–226.8 Gy). For
the subset of SBRT study arms with an EQD2,T for tumour >60 Gy
(24 studies, including 955 patients) the median FFLP was
90.6 ± 9.5% and for the accelerated schedules 87.6 ± 6.0% (Table 2).
As depicted in Fig. 1, there was no correlation between the FFLP
and the EQD2,T. A regression analysis showed no signiﬁcant rela-
tion between FFLP and the EQD2,T for all studies (r2 = 0.050;
p = 0.23) and for all studies with an EQD2,T for tumour >60 Gy
(r2 = 0.042; p = 0.32) (Fig. 1). Among the included fractionation
schedules, none was superior to the other. Supplementary regres-
sion analyses were performed to address the possibility that the
main regression analysis was affected by heterogeneity among
studies. None of the studies showed a signiﬁcant dose–response
relationship for FFLP when analysed separately (data not shown).
Also, a regression analysis stratiﬁed by study showed no signiﬁcant
relationship between FFLP and dose (data not shown).Discussion
For patients with clinical stage I and II non-small cell lung can-
cer, surgery remains the ﬁrst treatment of choice. However, for pa-
tients not ﬁt for surgery or those who refuse surgery, SBRT/SABR is
a good alternative [2–8]. Moreover, SBRT/SABR is a cost-effective
alternative with stable global quality of life during the ﬁrst year
after treatment [43,44]. However, conventional radiotherapy
schedules are often used in centrally located tumours due to pos-
sibly increased toxicity with hypo-fractionation in these cases
[9]. Alternatively ‘‘risk-adaptive strategies’’ for SBRT can be em-
ployed [20–23]. Haasbeek et al. describe e.g. a fractionation
scheme of 8 fractions of 7.5 Gy for patients with a tumour with a
hilar location or tumours adjacent to the pericardium or mediasti-
nal structures [23]. As the reported dose at the edge of the PTV
may have been overestimated in many SBRT series [8,25], the
Table 1
Study characteristics. TD = total dose, fd = fraction dose, FFLP = freedom from local progression, EQD2,T = equivalent dose in 2 Gy fractions corrected for overall treatment time.
Publication Total number of pt Number of pts TD Number of fr fd at edge PTV FFLP EQD2,T-edge PTV EQD2,T-late Therapeutic ratio
SBRT
1 Baumann (2006) 138 80 45 3 15.00 0.86 93.75 162.00 1.73
13 40 4 10.00 0.77 66.07 104.00 1.57
33 30 3 10.00 0.94 48.80 78.00 1.60
2 Baumann (2009) 57 57 45 3 15.00 0.92 91.35 162.00 1.77
3 Kopek (2009) 88 62 45 3 10.05 0.88 46.78 78.69 1.68
28 68 3 15.08 0.91 90.30 163.49 1.81
4 Koto (2007) 31 20 45 3 13.50 0.75 73.91 133.65 1.81
11 60 8 6.75 0.64 69.38 105.30 1.52
5 Nagata (2005) 45 45 48 4 10.53 0.98 64.81 113.88 1.76
6 Nyman (2006) 45 45 45 3 15.00 0.80 85.35 162.00 1.90
7 Onishi (2007) 257 55 48 4 10.80 0.97 65.28 119.23 1.83
54 73 10 6.53 0.73 79.65 124.30 1.56
44 60 8 6.75 0.91 64.58 105.30 1.63
24 63 5 11.25 1.00 88.21 160.31 1.82
19 50 5 9.00 0.84 59.25 108.00 1.82
16 40 4 9.00 0.49 44.40 86.40 1.95
10 48 8 5.40 0.55 42.24 72.58 1.72
8 Salazar (2008) 102 45 40 4 10.00 1.00 52.27 104.00 1.99
15 40 4 10.00 0.93 51.67 104.00 2.01
9 Takeda (2009) 63 63 50 5 10.00 0.95 67.13 130.00 1.94
10 Chen (2008) 26 10 66 11 5.70 0.90 62.83 109.10 1.74
15 64 8 7.60 0.92 69.37 128.90 1.86
1 48 6 7.60 1.00 46.48 96.67 2.08
11 Ricardi (20100 62 62 45 3 15.00 0.88 72.15 162.00 2.25
12 Matsuo (2011) 101 101 48 4 10.53 0.87 47.41 113.88 2.40
13 Videtic (2010) 28 28 50 5 9.50 0.94 51.39 118.75 2.31
14 Nagata (2010) 65 65 48 4 10.53 0.69 45.01 113.88 2.53
15 Timmerman (2010) 55 55 60 3 18.00 0.98 97.80 226.80 2.32
Accelerated fractionated RT
1 van Baardwijk (2010) 47 47 72 40 1.71 0.84 61.95 64.43 1.04
2 Bogart (2010) 39 39 70 40 2.89 0.92 117.47 136.04 1.16
Table 2
Results for all studies, SBRT studies, fractionated, accelerated studies and studies with an EQD2,T > 60 Gy. FFLP = freedom from local progression, EQD2,T = equivalent dose in 2 Gy
fractions corrected for overall treatment time. Results are expressed as median ± standard deviation (range).
Number of study
subsets
Total number
of pt
FFLP EQD2,T-tumour EQD2,T-late effects Therapeutic ratio
Median ± SD Median ± SD Median ± SD Median ± SD
(in %) (range) (in Gy) (range) (in Gy) (range) (range)
All studies 30 1160 88.0 ± 10.4 (49–
100)
76.6 ± 18.5 (50.0–
126.0)
119.2 ± 36.5 (64.4–
226.8)
1.8 ± 0.3 (1.5–
2.5)
All studies with an
EQD2 > 60 Gy
26 1039 90.4 ± 9.2 (63.6–
100)
82.8 ± 16.2 (61.9–
126.0)
124.3 ± 31.0 (64.4–
226.8)
1.8 ± 0.3 (1.5–
2.5)
All SBRT studies 28 1074 90.6 ± 9.5 (63.6–
100)
76.9 ± 17.4 (50.0–
126.0)
119.2 ± 35.4 (72.6–
226.8)
1.8 ± 0.3 (1.5–
2.5)
All SBRT studies with an
EQD2 > 60 Gy
24 953 88.0 ± 10.4 (49–
100)
82.9 ± 14.7 (66.7–
126.0)
124.3 ± 32.1 (96.7–
226.8)
1.9 ± 0.3 (1.5–
2.5)
All fractionated, accelerated
studies
2 86 87.6 ± 6.0 (83.8–
92.3)
86.9 ± 39.1 (61.9–
117.5)
96.6 ± 50.4 (64.4–
136.0)
1.7 ± 0.2 (1.5–
1.8)
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tion dose that is needed to eradicate early stage NSCLC. Should this
be the case, SBRT could be given at lower doses, thus improving the
therapeutic ratio further and allowing safe treatment also of cen-
tral small tumours with a few fractions.
For this reason, in this systematic review, we have re-calculated
the dose to the edge of the PTV in SBRT series with a long follow-up
and used our results to compare them to recent series that deliv-
ered accelerated radiotherapy with fraction sizes of around 2 Gy.
Ideally, individual dose distributions should have been available
to calculate the EUD and the inﬂuence of over- and under-dosage
at different points in the PTV, but this information was not avail-
able. We therefore chose the dose at the margin (‘‘edge’’) of the
PTV where the dose is the lowest and the underdosage due to
the use of older dose calculation algorithms is the highest. In manypatients, the maximum dose in the PTV may have been 30% higher
than at the edge [25]. The LQ model was employed to estimate the
EQD2,T, acknowledging that these tumour EQD2,T using large doses
per fraction are uncertain. Our estimates show that when ICRU 50
guidelines [45] are used, i.e. a minimum dose of 95% in the PTV, lo-
cal tumour control rates of over 90% could be obtained with EQD2,T
doses of about 65 Gy at the prescription point, irrespective
whether SBRT or accelerated high dose 3D conformal radiotherapy
(3D-RT) was given. This is of importance, since SBRT dose distribu-
tions are highly inhomogeneous compared with 3D-conformal
radiotherapy. The increased equivalent uniform dose delivered
using SBRT did not result in higher local tumour control. In this
reasoning, we assume that the radiosensitivity is uniformly distrib-
uted through the tumour, which may not be the case [46,47].
Moreover, it would be of interest to know what is the most related
0.0
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Fig. 1. EQD2 versus FFLP for SBRT studies (s) and fractionated, accelerated studies ( ). FFLP = freedom from local progression, EQD2 = equivalent dose in 2 Gy fractions. The
diameter of the circle represents the number of patients included in the speciﬁc study.
148 SBRT for stage I NSCLCto the tumour control probability: the dose at the edge of the PTV
or the uniform dose. As unavoidable steep dose-gradients occur at
the edge of the PTV, reliable information could come from prospec-
tive studies.
With local tumour control rates being already over 90%, it is
possible that the remaining local failure might be due to biological
(e.g. hypoxia) or technical factors such as a geographical miss. In
fact, all published series deliver doses that lead to very high local
tumour control rates and thus are located at the upper but shal-
low part of the dose–response curve. The ﬁnding that EQD2,T doses
of 65 Gy might sufﬁce to eradicate NSCLC tumours with diameters
up to 3 cm opens nevertheless the door to investigate lower doses
in this disease in a prospective clinical trial. Indeed, in centrally lo-
cated tumours, three fractions of 18 Gy resulted to too high an
incidence of severe side effects [9]. At present, there is not sufﬁ-
cient data to justify the use of gentler schedules such as 60 Gy
in 8 fractions when the PTV includes major parts of the main
bronchi or the oesophagus. The EQD2,T for the tumour
(a/b = 10 Gy) would be 81.3 Gy and for late responding tissues
(a/b = 3 Gy) it would be 115.4 Gy, exceeding tolerance levels
[48,49]. Therefore, from a theoretical point of view, a dose of
55 Gy given in 11 fractions of 5 Gy covering 95% of the PTV, would
be worth investigating. The EQD2,T for the tumour would be 64 Gy
and for late responding tissues it would be 81 Gy, just within
tolerance levels.
Obviously, our study has some drawbacks. First, the real doses
and dose distributions were estimated from the publication and
only in a minority we did have insight in what was actually given.
Second, techniques and dose calculations differ between studies,
which might inﬂuence the dose estimation at the edge of the target
volume [50,51]. We have tried to account for this, but our results
remain only estimations. Third, the linear quadratic model was
used. There is heterogeneity in the a/b values for tumours and or-
gans at risk (OARs) and the value of the model is uncertain for
doses per fraction above 10 Gy. Fourth, the deﬁnition of FFLP might
differ between studies: some authors only included local failure at
the site of the primary tumours others if a recurrence developed in
the same lobe. Moreover, the method of follow-up (regular imag-
ing or not) might inﬂuence the number of recurrences. Fifth, many
dose–response curves for NSCLC are derived from historical data of
which many also suffer from inaccurate dose calculation algo-
rithms. Our point estimates that are placed on these dose–response
curves should thus be interpreted with caution.In conclusion, published results in the literature do not support
the hypothesis of a positive dose–response relationship for tumour
control within the applied dose range. It might thus be possible to
reduce the dose to a level that still achieves tumour control rates in
excess of 90% in stage I NSCLC. This opens the possibility to embark
on clinical trials for central lesions with hypo-fractionated radio-
therapy at lower doses than are currently used.References
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